Product Information
THYROID 30 MG TABLET is a generic product labeled by Vitruvias Therapeutics Inc., priced at $0.5917 per EA under NDC 69680016600. Its NADAC has been published 81 times since Mar 19, 2025.
Strength
30 mg/1
Manufacturer
Vitruvias Therapeutics Inc.NDC
69680016600
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
THYROIDApproval Type
Unapproved
On Market Since
11/22/2024
Price Statistics
The NADAC for THYROID 30 MG TABLET has been published 81 times since Mar 19, 2025, and over the history we have for it it has declined 4.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5917 per EA |
|---|---|
| All-time high | $0.6219 (Jul 16, 2025) |
| All-time low | $0.5717 (Nov 19, 2025) |
| 52-week high | $0.5962 |
| 52-week low | $0.5717 |
| Median price | $0.5917 |
| Average price | $0.5969 |
| Largest weekly change | -4.4% (Sep 17, 2025) |
| Weeks tracked | 81 |
| Tracking since | Mar 19, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the THYROID market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Vitruvias Therapeutics Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
THYROID market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of THYROID 30 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for THYROID 30 MG TABLET, manufactured by Vitruvias Therapeutics Inc., is $0.5917 per EA (NDC 69680016600), effective Sep 30, 2026.
How has the price of THYROID 30 MG TABLET changed over time?
Over the history we have for it, the NADAC for THYROID 30 MG TABLET has declined 4.1%. It has been tracked across 81 weekly CMS publications since Mar 19, 2025.
What are the highest and lowest recorded NADAC prices for THYROID 30 MG TABLET?
Since Mar 19, 2025, the NADAC for THYROID 30 MG TABLET has ranged from a low of $0.5717 (Nov 19, 2025) to a high of $0.6219 (Jul 16, 2025), with a median of $0.5917 per EA.
Are there cheaper alternatives to THYROID 30 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of THYROID 30 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures THYROID 30 MG TABLET?
THYROID 30 MG TABLET (NDC 69680016600) is labeled by Vitruvias Therapeutics Inc., and CMS classifies it as a generic product.